Breakthrough Alert!  Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients

Breakthrough Alert!  Bringing New Hope to Relapsed and Refractory Multiple Myeloma Patients

Multiple Myeloma

   A recent milestone at the First Affiliated Hospital of Sun Yat-sen University in China marks a groundbreaking achievement in the treatment of relapsed and refractory multiple myeloma (R/RMM). Professor Li Juan and her team from the Hematology Department have successfully conducted the hospital’s inaugural Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) for this challenging condition, ushering in a new era of treatment prospects for R/RMM patients.

    Relapsed and refractory stages are often unavoidable in the progression of Multiple Myeloma, with limited treatment options and poor prognoses for patients upon entry into this phase. CAR-T therapy, a novel precision-targeted approach in cancer treatment, involves genetically engineering T-cells to restore their functionality, effectively targeting tumors with remarkable precision, speed, and efficiency. Both domestic and international studies have shown promising results for CAR-T therapy in R/RMM patients, making it one of the most effective treatments available for this condition.

     The first patient to undergo CAR-T therapy at our hospital was a 42-year-old male diagnosed with multiple myeloma two years prior at another medical institution. After undergoing conventional treatments for a period, including autologous hematopoietic stem cell transplantation, his disease unfortunately relapsed nine months post-transplant. Despite immediate intervention by experts, the disease was only briefly controlled, and the patient’s prognosis declined rapidly as he entered the refractory stage, with an estimated survival period of less than 20 months.

    With the approval of China’s first CAR-T BCMA multiple myeloma product, FUCASO, the patient and his family, after thorough consultations with healthcare professionals, opted for CAR-T therapy. Prior to treatment, the hematology team meticulously discussed potential complications and collaborated with relevant departments to establish comprehensive contingency plans. Following rigorous screening, lymphocyte collection, CAR-T cell preparation, and infusion, the patient smoothly progressed through the CAR-T cell infusion stage as planned.

     By the third week post-infusion, the patient experienced gradual relief from rib pain. On the 28th day post-infusion, bone marrow examination revealed no myeloma cells, and related indicators along with a full-body PET/CT scan indicated negativity for extramedullary lesions, showcasing significant treatment efficacy. The patient was successfully discharged, marking a triumphant milestone in his journey towards recovery.

     According to experts, with the continuous refinement of national guidelines for CAR-T cell therapy, the formal introduction of China’s first CAR-T product for myeloma treatment offers promising prospects for extending the survival period of domestic patients with refractory and relapsed multiple myeloma.

#CARTTherapy #MultipleMyeloma #CancerTreatment #HopeForPatients #MedicalBreakthrough #Hematology #PrecisionMedicine #HealthcareInnovation #MedicalResearch #SurvivalRates

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!

🌟✨ **Breakthrough! Chinese Novel CAR-T Therapy Kills Tumors and Prevents Relapse!** ✨🌟

CAR-T Therapy

🔬 On January 2, 2024, a groundbreaking clinical study from China was published in *Nature*. This study, employing engineering design, enables CAR-T cells to secrete Interleukin-10 (IL-10), thereby enhancing metabolism within the tumor microenvironment. The modified IL-10 CAR-T cells increase oxidative phosphorylation in a mitochondrial acetoacetate carrier-dependent manner, resulting in complete regression of solid tumors and metastatic cancers, including colon cancer, breast cancer, melanoma, and pancreatic cancer. This breakthrough research offers new hope for cancer patients.

🌱 **The Miracle of IL-10** 🌱

The secretion of IL-10 promotes the proliferation and effector functions of CAR T cells, leading not only to the regression of solid tumors but also inducing stem cell-like memory responses in lymphoid organs, providing enduring protection against tumor re-attack. Specifically, IL-10 HER2 CAR-T cells achieved complete regression of MC38-HER2 tumors in mice, with a cure rate of 90%. In the case of melanoma, IL-10 TRP-1 CAR-T cells achieved a clearance rate of 60%, with significant success in treating the orthotopic B16F10 melanoma model.

🦠 **A Weapon against Relapse** 🦠

In addition to complete regression of solid tumors, IL-10 CAR-T cells demonstrated the ability to prevent relapse in immunodeficient mice. Mice treated with IL-10 CD19 hCAR-T cells for Raji or PANC1-CD19 tumors exhibited complete tumor regression without relapse, indicating stronger anti-tumor capabilities of IL-10 CAR-T cells in xenograft models. Particularly noteworthy is the effective elimination of pancreatic ductal adenocarcinoma (PDAC) tumors by IL-10 CD19 hCAR-T cells, resulting in complete response in all treated mice.

💊 **A Revolutionary Treatment Approach** 💊

These findings suggest that IL-10-expressing CAR-T cells are an effective immunotherapy against various solid tumors, capable of achieving complete regression in multiple synthetic and xenograft tumor models. What’s more exciting is that preliminary results indicate the metabolism-enhanced IL-10 CD19 CAR-T cell therapy developed by Leman Biotech requires extremely low treatment doses, consistently achieving complete remission in numerous relapsed/refractory lymphoma or leukemia patients, paving the way for a new era in cancer treatment.

✨ **A Beacon of Hope** ✨

This breakthrough study brings hope to cancer patients and demonstrates the immense potential of CAR-T therapy in cancer treatment. Looking ahead, further advancements in this technology promise to provide more opportunities for recovery and survival to patients worldwide. Let’s anticipate more breakthroughs together and strive towards conquering cancer

 

To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#all #CARTtherapy #CancerTreatment #RRMM #IL10 #Tumor #Nature #MedicalBreakthrough #CARTCELL #coloncancer #breastcancer #melanoma #pancreatic 🌟🔬💊

10 months ago CAR-T , Leukemia

The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.

The new hope for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) boasts an overall survival rate of up to 96%.

    Recently, CAR-T cell therapy targeting B-cell malignancies has encountered a series of inquiries and challenges, particularly concerning discussions on CAR-T cell-related toxicity, resistance, antigen escape, and limitations in persistence. However, a groundbreaking concept addressing relapse in patients after CAR-T cell therapy has been introduced for the first time: a sequential approach involving distinct targeted CAR-T cell therapies.

    Within this approach, CD19 CAR-T cell therapy has demonstrated the ability to achieve complete remission in 60% to 90% of relapsed or refractory acute B-cell lymphoblastic leukemia patients. By experimenting with different combinations and sequential administration strategies of B-cell antigen-targeted CAR-T cell therapies, there’s potential to prevent tumor antigen escape and prolong the persistence of CAR-T cells.

    Preliminary clinical trials have provided initial support for this concept, notably a phase II clinical trial aimed at assessing the efficacy of sequential CD19 and CD22 CAR-T cell therapy. Its findings revealed a 79% event-free survival rate, an 80% sustained remission rate, and an impressive 96% overall survival rate among patients receiving targeted doses in sequential therapy. Encouragingly, the overall safety of this sequential therapy appeared manageable, providing long-term survival benefits for children with relapsed or refractory acute B-cell lymphoblastic leukemia.

However, the limitations of antigen escape and limited persistence after CAR-T cell therapy persist. Addressing these challenges, researchers have proposed the hypothesis of sequential administration of CAR-T cell products targeting different antigens, aiming to maintain the persistence of CAR-T cells.

    The results of this phase II clinical trial indicate that administering CD22 CAR-T cell therapy following CD19 CAR-T cell infusion can result in longer-lasting remission effects for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia, achieving an 80% sustained remission rate over 18 months and an impressive 96% overall survival rate. Importantly, the overall safety of this sequential therapy is uplifting, providing long-term survival benefits for this specific patient population.

    In summary, this study presents groundbreaking evidence for new strategies and directions in CAR-T cell therapy. Despite existing limitations, this therapy demonstrates significant potential in treating uncontrollable acute B-cell lymphoblastic leukemia, potentially offering more enduring treatment effects and long-term survival benefits for these patients. This achievement points towards a viable path for the future development of cell therapies.

    This Phase 2 trial, conducted at Beijing GoBroad Boren Hospital in China, enrolled pediatric patients aged 1–18 years diagnosed with relapsed or refractory B-cell acute lymphocytic leukaemia (ALL) showing CD19 and CD22 positivity exceeding 95%.

#CARTTherapy #PediatricCancer #CancerResearch #Immunotherapy #SequentialTherapy #ChildhoodCancer #HopeForPatients #MedicalBreakthrough #LeukemiaTreatment #LongTermSurvival #PrecisionMedicine #ClinicalTrials #Gobroad #Boren #HealthcareInnovation #CancerFree #ScienceAndMedicine